Vanda Pharmaceuticals (VNDA) Other Operating Expenses (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 17 years of Other Operating Expenses data on file, last reported at $5.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses fell 2.41% year-over-year to $5.1 million; the trailing twelve-month figure through Mar 2026 stood at $114.8 million (up 523.82% YoY), and the FY2025 full-year result was $114.9 million, up 518.29% from the prior year.
• Other Operating Expenses slipped to $5.1 million in Q1 2026, from $100.5 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $100.5 million in Q4 2025 to a low of $3.4 million in Q3 2023.
• A 5-year average of $10.7 million and a median of $5.1 million in 2026 frame the typical range for Other Operating Expenses.
• Across the five-year window, Other Operating Expenses sank 48.6% in 2023 and soared 2213.59% in 2025, its largest moves.
• Tracing VNDA's Other Operating Expenses over 5 years: stood at $6.6 million in 2022, then slumped by 33.31% to $4.4 million in 2023, then declined by 1.61% to $4.3 million in 2024, then soared by 2213.59% to $100.5 million in 2025, then plunged by 94.88% to $5.1 million in 2026.
• Business Quant data shows VNDA's Other Operating Expenses at $5.1 million in Q1 2026, $100.5 million in Q4 2025, and $4.7 million in Q3 2025.